Dianthus therapeutics completes enrollment of phase 2 magic trial of dnth103 in generalized myasthenia gravis with top-line results expected in september

Magic trial exceeded enrollment target of 60 patients top-line results anticipated this september will be the first of three dnth103 catalysts by ye'26 building a neuromuscular franchise with dnth103 in gmg, cidp and mmn with a potential  best-in-class, potent classical pathway inhibitor intended as a self-administered  autoinjector dosed once every two weeks new york and waltham, mass., may 05, 2025 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced completion of enrollment in the phase 2 magic trial of dnth103 in patients with generalized myasthenia gravis (gmg).
DNTH Ratings Summary
DNTH Quant Ranking